세계의 착상전 유전자 검사 시장 : 제품 및 서비스별, 기술별, 시술별, 용도별, 주기 유형별 - 예측(-2030년)

The preimplantation genetic testing market is expected to reach USD 1,135.0 million by 2030, up from USD 690.2 million in 2025, at a CAGR of 10.5% during the forecast period. The market growth is primarily driven by the increasing prevalence of genetic disorders, growing awareness regarding early genetic diagnosis, and the rising adoption of in-vitro fertilization (IVF) procedures worldwide.

The demand for preimplantation genetic testing is also supported by advancements in next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies that enhance testing accuracy and efficiency. Moreover, the growing trend toward delayed pregnancies and the rising risk of chromosomal abnormalities in embryos are contributing to the market expansion. However, the high costs associated with IVF and genetic testing procedures, along with ethical and regulatory challenges, continue to hinder widespread adoption.

"The aneuploidy application segment is expected to grow at the highest CAGR during the forecast period."

The aneuploidy application segment is projected to grow at the highest CAGR in the preimplantation genetic testing market during the forecast period. This growth is primarily driven by the rising incidence of chromosomal abnormalities, particularly among women of advanced maternal age, and the increasing demand for accurate embryo screening in IVF procedures. Aneuploidy enables the detection of abnormal chromosome numbers, helping improve implantation rates and reduce the risk of miscarriage. The integration of advanced genomic tools such as next-generation sequencing (NGS) and array-based comparative genomic hybridization (aCGH) has further enhanced test precision and efficiency. Additionally, growing awareness of genetic screening benefits and the rising adoption of assisted reproductive technologies are contributing to the strong growth of the aneuploidy segment globally.

"The reagents and consumables segment holds the largest share of the market."

The reagents and consumables segment holds the largest share of the preimplantation genetic testing market. This dominance is due to their repeated use at every stage of the testing process, including sample preparation, amplification, and analysis. The increasing number of IVF procedures and genetic tests has greatly boosted the demand for high-quality reagents, assay kits, and consumables that provide accuracy, reproducibility, and consistent results. Additionally, advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), and array-based platforms have enabled the development of specialized reagents for high-throughput and precise embryo analysis. Ongoing product innovations by major market players, along with the growing use of genetic screening in fertility clinics and research labs, further drive segment growth. The essential and recurring nature of these products secures their leading role in the global preimplantation genetic testing market.

"The US is expected to grow at the highest CAGR during the forecast period."

The US is expected to have the highest growth rate in the preimplantation genetic testing market, driven by several key factors. The strong presence of leading IVF clinics, advanced genomic labs, and a well-established healthcare system significantly contributes to market growth in the country. Additionally, the increasing rate of infertility, rising average maternal age, and growing awareness of genetic screening options are boosting demand for preimplantation genetic testing in the US. Favorable reimbursement policies, supportive government initiatives for reproductive health, and ongoing investments in genomic research further drive market expansion.

Furthermore, the growing integration of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies in IVF procedures is improving testing accuracy and efficiency. Increasing access to assisted reproductive technologies, along with the rising preference for personalized reproductive care, continues to drive the adoption of preimplantation genetic testing across the region. The US's robust regulatory framework ensures test reliability and clinical validity, bolstering confidence in preimplantation genetic testing solutions and reinforcing North America's leading position in the global market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1 - 25%, Tier 2 - 35%, and Tier 3 - 40%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, the Middle East - 10%, and Africa - 5%

Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), Abbott (US), Takara Bio Inc. (Japan), QIAGEN (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies plc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), Shiva Scientific (India), Nanjing Superyears Gene Technology Co. Ltd. (China), Medicover Genetics (Germany), MedGenome (India), Fulgent Genetics (US), Invicta (Poland), Genea Pty Limited (Australia), SciGene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co., Ltd. (China), GeneMind Biosciences Co. Ltd. (China), Berry Genomics (China), and Bangkok Genomics Innovation (Thailand) are some of the key companies offering preimplantation genetic testing products.

Research Coverage

This research report categorizes the preimplantation genetic testing market by procedure type (preimplantation genetic screening, preimplantation genetic diagnosis), technology (next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, single-nucleotide polymorphism), product & service (reagents & consumables, instruments, software & services), application (aneuploidy, structural chromosomal abnormalities [translocations, deletions, duplications, inversions], single gene disorders, X-linked disorders, HLA typing, gender identification), type of cycle (fresh non-donor, frozen non-donor, fresh donor, frozen donor), end user (fertility clinics, hospitals, diagnostic laboratories, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the preimplantation genetic testing market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the preimplantation genetic testing market. This report also includes a competitive analysis of emerging startups in the preimplantation genetic testing industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (decline in fertility, rise of fertility tourism in emerging economies, increasing number of fertility clinics and IVF centers, increasing public-private investments to develop novel diagnostic techniques, and high risk of chromosomal abnormalities with advancing maternal age), restraints (high procedural cost in preimplantation genetic testing and unfavorable government regulations and healthcare reforms for IVF procedures), opportunities (improving healthcare infrastructure and rising medical tourism in emerging economies and use of fertility treatments by single parents and same-sex couples), and challenges (socio-ethical concerns surrounding preimplantation genetic testing and procedural limitations with advancing age) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the preimplantation genetic testing market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the preimplantation genetic testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), and Abbott (US), among others offering products and services for preimplantation genetic testing market. Other companies include MedGenome (India), Fulgent Genetics (US), Invicta (Poland), Genea Pty Limited (Australia), SciGene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co., Ltd (China), and GeneMind Biosciences Co., Ltd. (China), among others, for the preimplantation genetic testing market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING PREIMPLANTATION GENETIC TESTING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SNAPSHOT

3 PREMIUM INSIGHTS

• 3.1 NORTH AMERICA: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE AND COUNTRY
• 3.2 PREIMPLANTATION GENETIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.3 PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY PRODUCT & SERVICE, 2025 VS. 2030 (%)
• 3.4 PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY END USER, 2024 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Decline in fertility rates
    • 4.2.1.2 Expanding network of fertility clinics and IVF centers
    • 4.2.1.3 Rising incidence of chromosomal abnormalities associated with advancing maternal age
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High procedural cost
    • 4.2.2.2 Stringent regulatory frameworks governing IVF and genetic testing procedures
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expanding acceptance of fertility treatments among single parents and same-sex couples
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Socio-ethical concerns regarding embryo screening and selection
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 GDP TRENDS & FORECAST
  • 5.2.2 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.3 R&D TRENDS IN GLOBAL PHARMA INDUSTRY
• 5.3 CASE STUDY ANALYSIS
  • 5.3.1 PGT-M FOR RPGRIP1L VARIANT-ENABLED BY MINIGENE ASSAY
  • 5.3.2 PERSISTENT FETAL MOSAICISM AFTER TRANSFER OF PGT-A MOSAIC EMBRYO
  • 5.3.3 CRYPTIC REARRANGEMENTS RESOLVED BY OGM TO GUIDE PGT-SR
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY END USER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.3 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING PRODUCTS, BY PROCEDURE TYPE, 2022-2024
  • 5.4.4 AVERAGE SELLING PRICE TREND OF PREIMPLANTATION GENETIC TESTING INSTRUMENTS AND CONSUMABLES, BY REGION, 2022-2024
• 5.5 TRADE ANALYSIS
  • 5.5.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
  • 5.5.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
  • 5.5.3 IMPORT DATA FOR HS CODE 9018, 2020-2024
  • 5.5.4 EXPORT DATA FOR HS CODE 9018, 2020-2024
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 ROLE IN ECOSYSTEM
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8.2 BARGAINING POWER OF SUPPLIERS
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 THREAT OF SUBSTITUTES
  • 5.8.5 THREAT OF NEW ENTRANTS
• 5.9 KEY CONFERENCES & EVENTS, 2025-2026
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 IMPACT OF 2025 US TARIFF ON PREIMPLANTATION GENETIC TESTING MARKET
  • 5.11.1 KEY TARIFF RATES
  • 5.11.2 PRICE IMPACT ANALYSIS
  • 5.11.3 KEY IMPACTS ON VARIOUS REGIONS
    • 5.11.3.1 US
    • 5.11.3.2 Europe
    • 5.11.3.3 Asia Pacific
  • 5.11.4 END-USE INDUSTRY IMPACT
    • 5.11.4.1 Fertility clinics
    • 5.11.4.2 Hospitals
    • 5.11.4.3 Diagnostic laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Laser-assisted TE biopsy
    • 6.1.1.2 Whole genome amplification
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Micromanipulation
• 6.2 TECHNOLOGY ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 METHODOLOGY
  • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 6.3.3 LIST OF KEY PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON PREIMPLANTATION GENETIC TESTING MARKET
  • 6.5.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.5.2 BEST PRACTICES IN AI-ENABLED EMBRYO SELECTION AND GENETIC SCREENING
  • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN PREIMPLANTATION GENETIC TESTING MARKET
  • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.5.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN PREIMPLANTATION GENETIC TESTING MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
      • 7.1.2.1.1 US
      • 7.1.2.1.2 Canada
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
      • 7.1.2.3.1 Japan
      • 7.1.2.3.2 China
      • 7.1.2.3.3 India
    • 7.1.2.4 Latin America
      • 7.1.2.4.1 Brazil
• 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT & SERVICE

• 9.1 INTRODUCTION
• 9.2 REAGENTS & CONSUMABLES
  • 9.2.1 EXPANSION OF ADVANCED GENOMIC TECHNOLOGIES TO PROMOTE MARKET GROWTH
• 9.3 INSTRUMENTS
  • 9.3.1 ONGOING TECHNOLOGICAL ADVANCEMENTS AND INCREASING FERTILITY CLINICS TO PROPEL MARKET GROWTH
• 9.4 SOFTWARE & SERVICES
  • 9.4.1 RISING AWARENESS ABOUT DATA ANALYSIS TO DRIVE MARKET

10 PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

• 10.1 INTRODUCTION
• 10.2 PREIMPLANTATION GENETIC SCREENING
  • 10.2.1 INCREASING MATERNAL AGE TO AID MARKET GROWTH
• 10.3 PREIMPLANTATION GENETIC DIAGNOSIS
  • 10.3.1 RISING AWARENESS ABOUT CHROMOSOMAL ABNORMALITIES IN FETUSES TO SUPPORT MARKET GROWTH

11 PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

• 11.1 INTRODUCTION
• 11.2 NEXT-GENERATION SEQUENCING
  • 11.2.1 IMPROVED TECHNOLOGY FOR DETECTING STRUCTURAL ABNORMALITIES TO FUEL MARKET GROWTH
• 11.3 POLYMERASE CHAIN REACTION
  • 11.3.1 INCREASED USAGE IN CLINICAL AND RESEARCH APPLICATIONS AND HIGH PREVALENCE OF GENETIC DISEASES TO SUPPORT MARKET
• 11.4 FLUORESCENCE IN SITU HYBRIDIZATION
  • 11.4.1 ADVANCES IN FLUORESCENCE MICROSCOPY AND DIGITAL IMAGING TO AUGMENT MARKET GROWTH
• 11.5 COMPARATIVE GENOMIC HYBRIDIZATION
  • 11.5.1 LOW COST, LESS LABOR REQUIREMENT, AND ONGOING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
• 11.6 SINGLE-NUCLEOTIDE POLYMORPHISM
  • 11.6.1 HIGH-RESOLUTION ACCURACY AND VALIDATED CLINICAL PERFORMANCE TO BOOST MARKET GROWTH

12 PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 ANEUPLOIDY
  • 12.2.1 HIGH ANEUPLOIDY INCIDENCE AND RAPID INNOVATION TO ACCELERATE MARKET GROWTH
• 12.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES
  • 12.3.1 TRANSLOCATIONS
    • 12.3.1.1 Rising incidence of translocation chromosomal abnormalities during IVF treatments to drive segment
  • 12.3.2 DELETIONS
    • 12.3.2.1 Advancements in genetic testing to boost segment growth
  • 12.3.3 DUPLICATIONS
    • 12.3.3.1 Rising cases of duplication of chromosomal abnormalities and increasing maternal age to drive segment
  • 12.3.4 INVERSIONS
    • 12.3.4.1 Risk of unexplained male-factor infertility and multiple miscarriages to limit segment growth
• 12.4 SINGLE GENE DISORDERS
  • 12.4.1 INCREASING AWARENESS ABOUT GENETIC TESTING TO PROPEL MARKET GROWTH
• 12.5 X-LINKED DISORDERS
  • 12.5.1 MEDICAL ADVANCEMENTS AND INCREASED RESEARCH ON GENETIC DISORDERS TO AUGMENT MARKET GROWTH
• 12.6 HLA TYPING
  • 12.6.1 RISING NUMBER OF COUPLES WITH CHILDREN AFFECTED BY HEMATOLOGICAL DISEASES TO DRIVE MARKET
• 12.7 GENDER IDENTIFICATION
  • 12.7.1 INCREASED FOCUS ON SEX DISCRIMINATION TO LIMIT MARKET GROWTH

13 PREIMPLANTATION GENETIC TESTING MARKET, BY TYPE OF CYCLE

• 13.1 INTRODUCTION
• 13.2 FRESH NON-DONOR
  • 13.2.1 HIGH RATES OF SUCCESSFUL PREGNANCY AMONG YOUNG WOMEN TO DRIVE MARKET GROWTH
• 13.3 FROZEN NON-DONOR
  • 13.3.1 LONG-TERM STORAGE OF FROZEN EGGS AND EASY SCHEDULING TO PROPEL MARKET GROWTH
• 13.4 FRESH DONOR
  • 13.4.1 HIGH-QUALITY FRESH DONOR OOCYTES AND EXPANDING PGT-DRIVEN RISK REDUCTION TO PROMOTE MARKET GROWTH
• 13.5 FROZEN DONOR
  • 13.5.1 RISING USE OF ADVANCED AND NON-INVASIVE PGT TECHNOLOGIES TO AID MARKET GROWTH

14 PREIMPLANTATION GENETIC TESTING MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 FERTILITY CLINICS
  • 14.2.1 HIGH SUCCESS RATE OF FERTILITY TREATMENT TO DRIVE MARKET
• 14.3 DIAGNOSTIC LABORATORIES
  • 14.3.1 IMPROVED CLINICAL EFFICACY AND INCREASED RESEARCH FUNDING TO FUEL MARKET
• 14.4 HOSPITALS
  • 14.4.1 RISING NUMBER OF HOSPITALS AND INCREASING HEALTHCARE AWARENESS TO DRIVE GROWTH
• 14.5 OTHER END USERS

15 PREIMPLANTATION GENETIC TESTING MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 US
    • 15.2.1.1 US to dominate North American preimplantation genetic testing market during forecast period
  • 15.2.2 CANADA
    • 15.2.2.1 Whole-genome embryo testing and public-private R&D investment to propel market growth
• 15.3 EUROPE
  • 15.3.1 GERMANY
    • 15.3.1.1 Global clinical adoption of precision medicines to boost market growth
  • 15.3.2 UK
    • 15.3.2.1 Demographic pressures and evidence-based clinical innovation to support market growth
  • 15.3.3 FRANCE
    • 15.3.3.1 Ethical regulation and adoption of patient-centered precision medicines to fuel market growth
  • 15.3.4 ITALY
    • 15.3.4.1 Regulatory reforms and clinical-genetic partnerships to boost market growth
  • 15.3.5 SPAIN
    • 15.3.5.1 Well-established network of research centers and universities to augment market growth
  • 15.3.6 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 CHINA
    • 15.4.1.1 Advancing next-generation genomic infrastructure and cross-border fertility capacity to propel market growth
  • 15.4.2 JAPAN
    • 15.4.2.1 Reinforcing global PGT standards and rigorous clinical governance to favor market growth
  • 15.4.3 INDIA
    • 15.4.3.1 Expanding genetic-diagnostic access to drive market growth
  • 15.4.4 AUSTRALIA
    • 15.4.4.1 Standardized regulation and expanding clinical adoption to fuel market growth
  • 15.4.5 SOUTH KOREA
    • 15.4.5.1 Clinically validated PGT-A integration and improved IVF outcomes to support market growth
  • 15.4.6 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 BRAZIL
    • 15.5.1.1 Global genomic innovation and regulatory modernization to boost market growth
  • 15.5.2 MEXICO
    • 15.5.2.1 Adoption of advanced NGS-based PGT services to support growth
  • 15.5.3 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 GCC COUNTRIES
    • 15.6.1.1 Kingdom of Saudi Arabia
      • 15.6.1.1.1 Rising global emphasis on preventive genomic medicine and advanced embryo-screening technologies to drive market
    • 15.6.1.2 UAE
      • 15.6.1.2.1 Rising global demand for safer and technologically advanced embryo screening to aid market growth
    • 15.6.1.3 Rest of GCC Countries
  • 15.6.2 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 REGIONAL ART REGISTRY EXPANSION AND RISING IVF INFRASTRUCTURE TO PROPEL MARKET GROWTH

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PREIMPLANTATION GENETIC TESTING MARKET
• 16.3 REVENUE ANALYSIS, 2020-2024
• 16.4 MARKET SHARE ANALYSIS, 2024
• 16.5 COMPANY VALUATION & FINANCIAL METRICS
  • 16.5.1 FINANCIAL METRICS
  • 16.5.2 COMPANY VALUATION
• 16.6 BRAND/PRODUCT COMPARISON
  • 16.6.1 ILLUMINA, INC.
  • 16.6.2 THERMO FISHER SCIENTIFIC INC.
  • 16.6.3 AGILENT TECHNOLOGIES, INC.
• 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 16.7.1 STARS
  • 16.7.2 EMERGING LEADERS
  • 16.7.3 PERVASIVE PLAYERS
  • 16.7.4 PARTICIPANTS
  • 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 16.7.5.1 Company footprint
    • 16.7.5.2 Region footprint
    • 16.7.5.3 Product & service footprint
    • 16.7.5.4 Technology footprint
    • 16.7.5.5 Application footprint
• 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 16.8.1 PROGRESSIVE COMPANIES
  • 16.8.2 RESPONSIVE COMPANIES
  • 16.8.3 DYNAMIC COMPANIES
  • 16.8.4 STARTING BLOCKS
  • 16.8.5 COMPETITIVE BENCHMARKING
    • 16.8.5.1 Detailed list of key startups/SMEs
    • 16.8.5.2 Competitive benchmarking of key startups/SMEs
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 ILLUMINA, INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products/Services/Solutions offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Deals
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 THERMO FISHER SCIENTIFIC INC.
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products/Services/Solutions offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 AGILENT TECHNOLOGIES, INC.
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products/Services/Solutions offered
    • 17.1.3.3 MnM view
      • 17.1.3.3.1 Key strengths
      • 17.1.3.3.2 Strategic choices
      • 17.1.3.3.3 Weaknesses & competitive threats
  • 17.1.4 REVVITY
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products/Services/Solutions offered
    • 17.1.4.3 MnM view
      • 17.1.4.3.1 Key strengths
      • 17.1.4.3.2 Strategic choices
      • 17.1.4.3.3 Weaknesses & competitive threats
  • 17.1.5 COOPERCOMPANIES
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products/Services/Solutions offered
    • 17.1.5.3 MnM view
      • 17.1.5.3.1 Key strengths
      • 17.1.5.3.2 Strategic choices
      • 17.1.5.3.3 Weaknesses & competitive threats
  • 17.1.6 ABBOTT
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products/Services/Solutions offered
  • 17.1.7 TAKARA BIO INC.
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products/Services/Solutions offered
  • 17.1.8 QIAGEN
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products/Services/Solutions offered
  • 17.1.9 VITROLIFE
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products/Services/Solutions offered
  • 17.1.10 OXFORD NANOPORE TECHNOLOGIES PLC
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products/Services/Solutions offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Expansions
• 17.2 OTHER PLAYERS
  • 17.2.1 OXFORD GENE TECHNOLOGY IP LIMITED
  • 17.2.2 YIKON GENOMICS
  • 17.2.3 SHIVA SCIENTIFIC
  • 17.2.4 NANJING SUPERYEARS GENE TECHNOLOGY CO., LTD.
  • 17.2.5 MEDICOVER GENETICS
  • 17.2.6 MEDGENOME
  • 17.2.7 FULGENT GENETICS
  • 17.2.8 INVICTA SP. Z O.O.
  • 17.2.9 GENEA PTY LIMITED
  • 17.2.10 SCIGENE CORPORATION
  • 17.2.11 BIOARRAY S.L.
  • 17.2.12 UNIMED BIOTECH (SHANGHAI) CO., LTD.
  • 17.2.13 GENEMIND BIOSCIENCES CO., LTD.
  • 17.2.14 BERRY GENOMICS
  • 17.2.15 BANGKOK GENOMICS INNOVATION

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS